Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Knowledge translation in tri-sectoral collaborations: An exploration of perceptions of academia, industry and healthcare collaborations in innovation adoption.

Ii SS, Fitzgerald L, Morys-Carter MM, Davie NL, Barker R.

Health Policy. 2018 Feb;122(2):175-183. doi: 10.1016/j.healthpol.2017.11.010. Epub 2017 Nov 24.

PMID:
29191387
2.

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24.

3.

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim NH, D'Armini AM, Grimminger F, Grünig E, Hoeper MM, Jansa P, Mayer E, Neurohr C, Simonneau G, Torbicki A, Wang C, Fritsch A, Davie N, Ghofrani HA.

Heart. 2017 Apr;103(8):599-606. doi: 10.1136/heartjnl-2016-309621. Epub 2016 Dec 23.

4.

Leisure Time Activities and Mental Health in Informal Dementia Caregivers.

Schüz B, Czerniawski A, Davie N, Miller L, Quinn MG, King C, Carr A, Elliott KE, Robinson A, Scott JL.

Appl Psychol Health Well Being. 2015 Jul;7(2):230-48. doi: 10.1111/aphw.12046. Epub 2015 Jun 11.

PMID:
26097155
5.

Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.

D'Armini AM, Ghofrani HA, Kim NH, Mayer E, Morsolini M, Pulido-Zamudio T, Simonneau G, Wilkins MR, Curram J, Davie N, Hoeper MM.

J Heart Lung Transplant. 2015 Mar;34(3):348-55. doi: 10.1016/j.healun.2015.02.003. Epub 2015 Feb 16.

6.

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.

Langleben D, Galiè N, He J, Huang Y, Humbert M, Keogh A, Rubin LJ, Zhou D, Curram J, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2015 Mar;34(3):338-47. doi: 10.1016/j.healun.2014.12.001. Epub 2014 Dec 12.

7.

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).

Rubin LJ, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh A, Langleben D, Fritsch A, Menezes F, Davie N, Ghofrani HA.

Eur Respir J. 2015 May;45(5):1303-13. doi: 10.1183/09031936.00090614. Epub 2015 Jan 22.

8.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Hoeper MM, Jansa P, Kim NH, Wang C, Wilkins MR, Fritsch A, Davie N, Colorado P, Mayer E.

Eur Respir J. 2015 May;45(5):1293-302. doi: 10.1183/09031936.00087114. Epub 2014 Nov 13.

9.

Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.

Kojonazarov B, Sydykov A, Pullamsetti SS, Luitel H, Dahal BK, Kosanovic D, Tian X, Majewski M, Baumann C, Evans S, Phillips P, Fairman D, Davie N, Wayman C, Kilty I, Weissmann N, Grimminger F, Seeger W, Ghofrani HA, Schermuly RT.

Int J Cardiol. 2013 Sep 10;167(6):2630-7. doi: 10.1016/j.ijcard.2012.06.129. Epub 2012 Jul 31.

PMID:
22854298
10.

A decade of cell therapy clinical trials (2000-2010).

Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C.

Regen Med. 2012 Jul;7(4):455-62. doi: 10.2217/rme.12.45. No abstract available.

11.

Promising growth and investment in the cell therapy industry during the first quarter of 2012.

Brindley DA, Davie NL, Sahlman WA, Bonfiglio GA, Culme-Seymour EJ, Reeve BC, Mason C.

Cell Stem Cell. 2012 May 4;10(5):492-6. doi: 10.1016/j.stem.2012.04.018.

12.

Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.

Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):716-22. doi: 10.1016/j.lfs.2012.02.003. Epub 2012 Feb 18.

13.

Peak serum: implications of serum supply for cell therapy manufacturing.

Brindley DA, Davie NL, Culme-Seymour EJ, Mason C, Smith DW, Rowley JA.

Regen Med. 2012 Jan;7(1):7-13. doi: 10.2217/rme.11.112. Review. No abstract available.

PMID:
22168489
14.

The impact of market volatility on the cell therapy industry.

Brindley DA, Reeve BC, Sahlman WA, Bonfiglio GA, Davie NL, Culme-Seymour EJ, Mason C.

Cell Stem Cell. 2011 Nov 4;9(5):397-401. doi: 10.1016/j.stem.2011.10.010. Review.

15.

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.

Kosanovic D, Kojonazarov B, Luitel H, Dahal BK, Sydykov A, Cornitescu T, Janssen W, Brandes RP, Davie N, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT.

Respir Res. 2011 Jun 23;12:87. doi: 10.1186/1465-9921-12-87.

16.

Cell therapy industry: billion dollar global business with unlimited potential.

Mason C, Brindley DA, Culme-Seymour EJ, Davie NL.

Regen Med. 2011 May;6(3):265-72. doi: 10.2217/rme.11.28. No abstract available.

17.

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.

Hall SM, Davie N, Klein N, Haworth SG.

Eur Respir J. 2011 Oct;38(4):851-60. doi: 10.1183/09031936.00167010. Epub 2011 Mar 15.

18.

Regenerative medicine through a crisis: social perception and the financial reality.

Brindley D, Davie N.

Rejuvenation Res. 2009 Dec;12(6):455-61. doi: 10.1089/rej.2009.0981.

PMID:
20041739
19.

The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.

Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA.

Eur J Clin Invest. 2009 Jun;39 Suppl 2:38-49. doi: 10.1111/j.1365-2362.2009.02120.x. Review. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.

PMID:
19335746
20.

Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1.

Davie NJ, Gerasimovskaya EV, Hofmeister SE, Richman AP, Jones PL, Reeves JT, Stenmark KR.

Am J Pathol. 2006 Jun;168(6):1793-807.

21.

Role of the adventitia in pulmonary vascular remodeling.

Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M.

Physiology (Bethesda). 2006 Apr;21:134-45. Review.

22.

Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage.

Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR.

Am J Pathol. 2006 Feb;168(2):659-69.

23.

Extracellular adenosine triphosphate: a potential regulator of vasa vasorum neovascularization in hypoxia-induced pulmonary vascular remodeling.

Gerasimovskaya EV, Davie NJ, Ahmad S, Tucker DA, White CW, Stenmark KR.

Chest. 2005 Dec;128(6 Suppl):608S-610S. Review. No abstract available.

PMID:
16373860
24.

Circulating mononuclear cells with a dual, macrophage-fibroblast phenotype contribute robustly to hypoxia-induced pulmonary adventitial remodeling.

Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Stenmark KR.

Chest. 2005 Dec;128(6 Suppl):583S-584S. No abstract available.

PMID:
16373848
25.

Hypoxia, leukocytes, and the pulmonary circulation.

Stenmark KR, Davie NJ, Reeves JT, Frid MG.

J Appl Physiol (1985). 2005 Feb;98(2):715-21. Review.

26.

Axotomy-dependent and -independent synapse elimination in organ cultures of Wld(s) mutant mouse skeletal muscle.

Parson SH, Ribchester RR, Davie N, Gandhi NP, Malik RQ, Gillingwater TH, Thomson D.

J Neurosci Res. 2004 Apr 1;76(1):64-75.

PMID:
15048930
27.

Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.

Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR.

Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L668-78. Epub 2003 May 16.

28.

Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells.

Yang X, Sheares KK, Davie N, Upton PD, Taylor GW, Horsley J, Wharton J, Morrell NW.

Am J Respir Cell Mol Biol. 2002 Dec;27(6):688-96.

PMID:
12444028
29.

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J.

Am J Respir Crit Care Med. 2002 Feb 1;165(3):398-405.

PMID:
11818328
30.

Differential adrenomedullin release and endothelin receptor expression in distinct subpopulations of human airway smooth-muscle cells.

Upton PD, Wharton J, Davie N, Ghatei MA, Smith DM, Morrell NW.

Am J Respir Cell Mol Biol. 2001 Sep;25(3):316-25.

PMID:
11588009
31.

Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations.

Upton PD, Wharton J, Coppock H, Davie N, Yang X, Yacoub MH, Ghatei MA, Polak JM, Bloom SR, Smith DM, Morrell NW.

Am J Respir Cell Mol Biol. 2001 Feb;24(2):170-8.

PMID:
11159051
32.

Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery.

Borland JA, Chester AH, Rooker SJ, Wharton J, Davie N, Amrani M, Yacoub MH.

Ann Thorac Surg. 2000 Dec;70(6):2054-63.

PMID:
11156120
33.

Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells.

Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW.

Circulation. 2000 Dec 19;102(25):3130-6.

PMID:
11120706
34.

Practical Hints on the Management of Normal and Complicated Breech Cases.

Davie N.

Hospital (Lond 1886). 1908 Aug 29;44(1149):581-582. No abstract available.

Supplemental Content

Support Center